Publications
June 28, 2022
PVRIG and TIGIT immune checkpoint blockade in cancer: Emerging translational data from clinical trials
Pierre Ferré, AIS 2022 Montpellier, France, 28 June 2022
April 11, 2022
Poster: The Expression of the PVRIG/TIGIT Pathway is Dominant in the Bone Marrow of Patients with Multiple Myeloma
Masha Frenkel et al, AACR annual meeting, April 08-13, 2022
March 21, 2022
Poster: Exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics
Roy Granit, et al, Keystone Symposium on Cancer Immunotherapy, March 20-24, 2022
March 21, 2022
Presentation: Exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics
Roy Granit, et al, Keystone Symposium on Cancer Immunotherapy, March 20-24, 2022
March 14, 2022
Abstract: Exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics
Roy Granit, et al, Keystone Symposium on Cancer Immunotherapy, March 20-24, 2022
March 9, 2022
Abstract: The Expression of the PVRIG/TIGIT Pathway is Dominant in the Bone Marrow of Patients with Multiple Myeloma
Masha Frenkel et al, AACR annual meeting, April 08-13, 2022
December 9, 2021
Harnessing PVRIG & TIGIT Combination in Anti-Cancer Immunity
Eran Ophir, VP Research & Drug Discovery, TIGIT Therapies Digital Summit
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (video)
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
